Results 141 to 150 of about 1,431,287 (296)

Performance Characteristics of Anti‐Collagen II Antibodies in Relapsing Polychondritis and Related Diseases: Prospective Analysis, Systematic Review, and Meta‐Analysis

open access: yesArthritis Care &Research, Accepted Article.
Background Relapsing polychondritis (RP) is a rare disease defined by recurrent cartilaginous inflammation. Anti‐collagen II (anti‐Col2) antibodies have been proposed as a diagnostic biomarker for RP, but their performance characteristics are not well defined.
Karyssa Stonick   +6 more
wiley   +1 more source

The pathogenesis of anti-signal recognition particle necrotizing myopathy: A Review

open access: gold, 2022
Ruqing Qiu   +5 more
openalex   +1 more source

On Pathogenesis [PDF]

open access: yesDeutsches Ärzteblatt international, 2016
openaire   +2 more sources

Diagnostic Utility of Testing for Novel Murine Autoantibodies for Sjögren's Disease in the Rheumatology Outpatient Setting

open access: yesArthritis Care &Research, Accepted Article.
Objective The goal was to assess the diagnostic performance of three novel autoantibodies (NA) for Sjögren's disease (SjD) by comparing NA prevalence in patients with SjD, other autoimmune rheumatic diseases (ARDs), nonspecific chronic sialadenitis (CS), and controls.
Chadwick R. Johr   +5 more
wiley   +1 more source

Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus [PDF]

open access: gold, 2019
Yiyangzi Ma   +5 more
openalex   +1 more source

Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis‐Associated Interstitial Lung Disease Risk

open access: yesArthritis Care &Research, Accepted Article.
Objective The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase (MMP)‐7, and serum anti‐malondialdehyde‐acetaldehyde (anti‐MAA) antibody for RA‐associated interstitial lung disease risk stratification. Methods Using a multicenter cohort of US veterans with RA, we performed a cross‐
Kelsey Coziahr   +16 more
wiley   +1 more source

MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY

open access: yesArthritis Care &Research, Accepted Article.
Objective Mycophenolate Mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon due to the lower fibrotic burden and the predominance of the vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis   +77 more
wiley   +1 more source

Home - About - Disclaimer - Privacy